John A Vargo1, Vitali Moiseenko2, Jimm Grimm3, Jimmy Caudell4, David A Clump5, Ellen Yorke6, Jinyu Xue7, Yevgeniy Vinogradskiy8, Eduardo G Moros4, Panayiotis Mavroidis9, Sheena Jain10, Issam El Naqa11, Lawrence B Marks9, Dwight E Heron12. 1. Department of Radiation Oncology, West Virginia University, Morgantown, West Virginia. 2. Radiation Medicine & Applied Sciences, University of California, San Diego, La Jolla, California. 3. Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, Baltimore, Maryland. 4. H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida. 5. Department of Radiation Oncology, UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. 6. Memorial Sloan Kettering Cancer Center, New York, New York. 7. Department of Radiation Oncology, M. D. Anderson Cancer Center at Cooper University Hospital, Camden, New Jersey. 8. Department of Radiation Oncology, University of Colorado Denver, Aurora, Colorado. 9. Department of Radiation Oncology and Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina. 10. Bott Cancer Center, Holy Redeemer Hospital, Meadowbrook, Pennsylvania. 11. University of Michigan, Ann Arbor, Michigan. 12. Department of Radiation Oncology, UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. Electronic address: herond2@umpc.edu.
Abstract
PURPOSE: Stereotactic body radiation therapy (SBRT) has emerged as a viable reirradiation strategy for locally recurrent previously-irradiated head and neck cancer. Doses in the literature have varied, which challenges clinical application of SBRT as well as clinical trial design. MATERIAL & METHODS: A working group was formed through the American Association of Physicists in Medicine to study tumor control probabilities for SBRT in head and neck cancer. We herein present a systematic review of the available literature addressing the dose/volume data for tumor control probability with SBRT in patients with locally recurrent previously-irradiated head and neck cancer. Dose-response models are generated that present tumor control probability as a function of dose. RESULTS: Data from more than 300 cases in 8 publications suggest that there is a dose-response relationship, with superior local control and possibly improved overall survival for doses of 35 to 45 Gy (in 5 fractions) compared with <30 Gy. CONCLUSION: Stereotactic body radiation therapy doses equivalent to 5-fraction doses of 40 to 50 Gy are suggested for retreatment.
PURPOSE: Stereotactic body radiation therapy (SBRT) has emerged as a viable reirradiation strategy for locally recurrent previously-irradiated head and neck cancer. Doses in the literature have varied, which challenges clinical application of SBRT as well as clinical trial design. MATERIAL & METHODS: A working group was formed through the American Association of Physicists in Medicine to study tumor control probabilities for SBRT in head and neck cancer. We herein present a systematic review of the available literature addressing the dose/volume data for tumor control probability with SBRT in patients with locally recurrent previously-irradiated head and neck cancer. Dose-response models are generated that present tumor control probability as a function of dose. RESULTS: Data from more than 300 cases in 8 publications suggest that there is a dose-response relationship, with superior local control and possibly improved overall survival for doses of 35 to 45 Gy (in 5 fractions) compared with <30 Gy. CONCLUSION: Stereotactic body radiation therapy doses equivalent to 5-fraction doses of 40 to 50 Gy are suggested for retreatment.
Authors: Diane C Ling; John A Vargo; Rachel J Grimm; Brian J Gebhardt; David A Clump; Robert L Ferris; James P Ohr; Dwight E Heron Journal: J Radiosurg SBRT Date: 2020
Authors: Yijun Ding; Harrison H Barrett; Matthew A Kupinski; Yevgeniy Vinogradskiy; Moyed Miften; Bernard L Jones Journal: Med Phys Date: 2019-06-07 Impact factor: 4.071
Authors: Diane C Ling; John A Vargo; Brian J Gebhardt; Rachel J Grimm; David A Clump; Robert L Ferris; James P Ohr; Dwight E Heron Journal: J Radiosurg SBRT Date: 2019
Authors: Jimm Grimm; Lawrence B Marks; Andrew Jackson; Brian D Kavanagh; Jinyu Xue; Ellen Yorke Journal: Int J Radiat Oncol Biol Phys Date: 2021-05-01 Impact factor: 8.013
Authors: Vitali Moiseenko; Lawrence B Marks; Jimm Grimm; Andrew Jackson; Michael T Milano; Jona A Hattangadi-Gluth; Minh-Phuong Huynh-Le; Niclas Pettersson; Ellen Yorke; Issam El Naqa Journal: Int J Radiat Oncol Biol Phys Date: 2020-12-23 Impact factor: 8.013
Authors: Michael Green; Samantha J Van Nest; Emilie Soisson; Kathryn Huber; Yixiang Liao; William McBride; Michael M Dominello; Jay Burmeister; Michael C Joiner Journal: J Appl Clin Med Phys Date: 2020-06 Impact factor: 2.102
Authors: Olgun Elicin; Paul Martin Putora; Marco Siano; Martina A Broglie; Christian Simon; Daniel Zwahlen; Gerhard F Huber; Giorgio Ballerini; Lorenza Beffa; Roland Giger; Sacha Rothschild; Sandro V Negri; Pavel Dulguerov; Guido Henke Journal: Front Oncol Date: 2019-10-24 Impact factor: 6.244
Authors: Muhammad Shahid Iqbal; Nick West; Neil Richmond; Josef Kovarik; Isabel Gray; Nick Willis; David Morgan; Gozde Yazici; Mustafa Cengiz; Vinidh Paleri; Charles Kelly Journal: Br J Radiol Date: 2020-09-24 Impact factor: 3.039